Retired CFO
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Cord Blood America CEO Matthew Schissler to Speak at Nevada Development Authority Celebration
LAS VEGAS, June 9, 2010 /PRNewswire via COMTEX/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI) (www.cordblood-america.com) co-founder and CEO Matthew Schissler speaks today at a joint media event of the Nevada Development Authority and the Las Vegas Convention and Visitors Authority about the economic advantages for Cord Blood America to move from Southern California to Nevada.
The event, which features the top leaders of the Development Authority, the Convention and Visitors Authority, and Las Vegas city officials, emphasizes that Nevada is now ranked number two in the nation for favorable business climates.
Factors considered in the ranking include state and local taxes, regulatory costs, and health care and energy costs. Nevada has no corporate or personal income tax and works hard to avoid placing unnecessary burdens on entrepreneurship and small business, its officials emphasized.
"I am just incredibly honored to speak from the same podium as the business and political elite from Las Vegas. I express great gratitude to the Nevada Development Authority, a truly exceptional organization, to have highlighted Cord Blood America as an example of the great strides they are taking to increase and diversify the business base of Las Vegas," Mr. Schissler will tell the media event. "These are among the reasons we moved to Nevada and we are very pleased that we did. We have found a workforce that is talented and eager to help a small company grow into an international powerhouse. That is what Cord Blood America is all about and we appreciate the Nevada spirit that allows us to expand and succeed."
Cord Blood America is the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com) focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally.
I'm not sure what you mean. I expected Buyins to lower the Squeeze Trigger number as when they set the penny number we were at .0078. Now we're at .0062 so common sense tells me the number should be lower. But .0097 isn't much of a change. Was hoping for much lower like .0085. We clearly got Buyins attention though and that is all we could hope for.
Yeah. If I had an extra million dollars laying around we could do some real damage to those MM's. The only way I see us breaking this short attack would be to have a beneficial owner join the party. Otherwise, I'm affraid it's up to the MM's to stop this or maybe Buyins helps in ways we don't understand.
Yeah. Obviously they reacted to our anger. But I was hoping for something closer to .0085.
Thanks from the US.
I think he said "cash flow neutral" but could be wrong. I'm sure that's what he meant anyway.
Well I was hoping for a lower Squeeze Trigger number but at least Buyins got the message and hopefully it will help us break this short attack soon.
57% short volume today.
CBAI|13365347|23545734
I took this as a hopefull sign the Squeeze Trigger number will be adjusted downward. Can't hurt.
We will update the report very soon.
Tom
A little complaining never hurt. His last email to me promised new stuff soon and I'm assuming it will be a lower Squeeze Trigger number. Our day is coming.
His response.
We will update the report very soon.
Tom
My last email to Tom at Buyins.
Sure seems to me the Squeeze Trigger should be lowered considering where this has gone from the time you originally assessed it.
Dewey
Latest response.
I understand your frustration but please don't take it out on us. We work very hard to help CBAI and to have negative feedback actually hinders our efforts. But I do appreciate your understanding as our emails have unfolded. We will beat the shorts and we are in contact with CBAI daily about what we are doing.....
Tom
Seems to me they should lower the Squeeze Trigger number since we were in the high .007's when we hired them and now we're in the low .006's. There number at the time was .01.
That was basically my last email to them. The Stock Squeeze Trigger is a penny and we're getting further and further away from that. So what the hell are they doing?
At least he knows we're paying attention. I'm sure they don't want bad press.
Read my post just before your post.
Below is his latest and long response.
When CBAI goes above the SqueezeTrigger Price you will see what we do for a living. Until then, read this: There are nearly 14 years behind what we do. I lobbied from 1996 to 2004 to create Regulation SHO. They passed the law in 2005 and when I saw the SEC was not enforcing their own rule, I built BUYINS.NET in April 2005 to enforce it myself. Harvey Pitt (ex head of SEC) became my partner in January 2006 and we have spent the last 5 years building a 720,000 retail investor following and 35,000 institutional investors. We also recently were able to pass a new law called the FAIR MARKET MAKING REQUIREMENT (read language at end of email). We are approved by Yahoo Finance as 1 of 43 news providers to Yahoo so our reports show up in the stock symbol when we issue them. There are 16.5 million websites carrying our content. As a matter of comparison, CNBC.COM has 4.04 million websites carrying their content. Buyins.net 16.5 millionBloomberg.com 7.07 millionWSJ.com 5.01 millionCnbc.com 4.04 millionMorningstar.com 1.8 millionBarrons.com 1.35 millionThomsonfinancial.com 813kIBD.com 799kZacks.com 752kFoxbusiness.com 685k When we issue reports 2 things happen: 1. PEOPLE READ THEM2. PEOPLE TRUST AND BELIEVE IN WHAT WE ARE SAYING Hence, when you look at the time and date stamp on when our reports cross the newswires and compare them to the trading charts, there is no denying that we generate enough buying interest to get the stock moving. And when your stock crosses a SqueezeTrigger Level, the shorts do 2 things: 1. THEY STOP SHORTING2. THEY START COVERING This creates an exponential effect of the offers going away and the bids stepping up. The price goes higher. It is that simple :) Here's an update on the 15 short squeezes we have caused in our latest SqueezeTrigger reports: SWRS +170% in 4 hours of first day of report! Chart: http://www.buyins.com/images/swrschart5-20-10.jpg Report: http://finance.yahoo.com/news/BUYINSNET-Issues-Southwest-pz-1520906003.html?x=0&.v=1 UEC +10.9% ($2.75 to $3.50) in 2 trading days Chart: http://www.buyins.com/images/uecchart5-11-10.jpg Report: http://finance.yahoo.com/news/BUYINSNET-Issues-Uranium-pz-1912414675.html?x=0&.v=1 XDSL +17% ($.018 to $.021) in two days on 12.5 million shares traded Chart: http://www.buyins.net/images/xdslchart4-20-10.jpg Report: http://finance.yahoo.com/news/BUYINSNET-Issues-mPhase-pz-103830657.html?x=0&.v=1 CRWG +12.2% ($1.31 to $1.47) in one day since our report. This is a $6.25 million gain in market cap in just 6.5 trading hours! Chart: http://www.buyins.com/images/crwgchart4-15-10.jpg Report: http://finance.yahoo.com/news/BUYINSNET-Issues-CrowdGather-pz-4195077140.html?x=0&.v=1 POPN +54% ($.0033 to $.0051) in 4 trading days on 24 million shares traded. Chart: http://www.buyins.com/images/popnchart4-17-10.jpg Report: http://www.buyins.com/reports/popn4-15-10.pdf MTPR +22.86% $.0035 to $.0043 on 4.13 million shares in first 4 hours of report Chart: http://www.buyins.com/images/mtprchart4-12-10.jpg Report: http://finance.yahoo.com/news/BUYINSNET-Issues-MetaPower-pz-3138362553.html?x=0&.v=1 UNDT +108% from $.0023 to $.0048 on over 156 million shares traded Chart: http://www.buyins.com/images/undtchart4-17-10.jpg Report: http://www.buyins.com/reports/undt3-29-10.pdf GCKO +535% from $.016 to $.10 on over 10.5 million shares traded Chart: http://www.buyins.com/images/gckochart4-7-10.jpg Report: http://finance.yahoo.com/news/BUYINSNET-Issues-GeckoSystems-pz-3004874124.html?x=0&.v=1 BEDA +37% from $.0016 to $.0022 on over 817 million shares traded Chart: http://www.buyins.com/images/bedachart4-7-10.jpg Report: http://finance.yahoo.com/news/BUYINSNET-Issues-Bederra-Corp-pz-717501688.html?x=0&.v=1 XPGH +93% from $0.155 to $0.30 Chart: http://www.buyins.com/images/xpghchart4-6-10.jpg Report: http://finance.yahoo.com/news/BUYINSNET-Issues-Xcelplus-pz-1286921816.html?x=0 MSEH +43% from $2.27 to $3.27 on over 4.3 million shares traded: Chart: http://www.buyins.com/images/msehchart3-31-10.jpg Report: http://www.buyins.com/reports/mseh3-26-10.pdf IVIT quadruples (+300%) from $.0003 to $.0012 on over 2.2 billion shares traded Chart: http://www.buyins.com/images/ivitchart3-26-10.jpg Report: http://finance.yahoo.com/news/BUYINSNET-Issues-Invicta-pz-3768072562.html?x=0&.v=1 URZ +100% ($1.12 to $2.24) in just over 1 month! Chart: http://www.buyins.com/images/urzchart1-28-10.jpg Report: http://finance.yahoo.com/news/BUYINSNET-Issues-Uranerz-pz-466067885.html?x=0&.v=2 RMDM +100% since March 11th on over 2.3 billion shares traded Chart: http://www.buyins.com/images/rmdmchart3-26-10.jpg Report: http://www.quote.com/news/story.action?id=PMZ070u5014 MDFI +30% in one day, from $.0096 to $.0125 Chart: http://www.buyins.com/images/mdfichart3-22-10.jpg Report: http://finance.yahoo.com/news/BUYINSNET-Issues-MedeFile-pz-2184729329.html?x=0&.v=1 And here is the language from the FAIR MARKET MAKING REQUIREMENT that we were able to get included in the Amended Regulation SHO. Because market makers do 60-70% of the shorting in the stock, we will use the law we helped get passed to bring them back into compliance in trading your stock. Read the new rule: On October 17, 2008 the SEC passed these final amendments to Regulation SHO: http://www.sec.gov/rules/final/2008/34-58775.pdf Page 29 Section IV Bona-Fide Market Making addresses that bona-fide market making activities include making purchases and sales in roughly comparable amounts. The Commission has stated that bona-fide market making DOES NOT include activity that is related to speculative selling strategies or investment purposes of the broker-dealer and is disproportionate to the usual market making patterns or practices of the broker-dealer in that security. Likewise, where a market maker posts continually at or near the best offer, but does not also post at or near the best bid, the market maker’s activities would not generally qualify as bona-fide market making. Moreover, a market maker that continually executes short sales away from its posted quotes would generally not be considered to be engaging in bona-fide market making.
Well I just sent him an email back and said why don't you just tell me what you're doing for CBAI cause the shorting certainly hasn't slowed down.
http://www.buyins.net/
Tom Ronk
CEO
tom@buyins.net
OK, so I got a quick response from Buyins. Funny but now I'm also having a problem accessing there site. Did they block me? LOL. So any suggestions for questions/comments? Below is his response.
Thank you for your spirited email. I would be happy to help you understand what we are doing on DAILY basis for CBAI. And what goes on in the background with regulators, lobbying the SEC, pressuring market makers etc. But first, so that I understand who I am talking to; please tell me what you think we do for a living so I can tell if you have a complete understanding of Buyins.net and our services.
Thanks,
Tom RonkCEOtom@buyins.net
Just to make me feel better I just sent a rather angry email to Buyins.net telling them what a waste of money it was to hire them. The shorting is totally out of control. But I do agree with you that this is a long-term hold no doubt. The financials are going to get better every quarter and soon we will turn a profit. As those things occur we will see this go up for sure.
Morning all. I'm becoming confused over this shorting thing. Seems everyday the MM's are shorting this stock but at some point they must also be covering or they would have a FTD problem by now. If anyone understands all this please explain. Also, where can I find the FTD list that you say you check regularly? Thanks.
I doubt he qualifies for that kind of job but seems there was more short selling today. 50%
CBAI|15346287|30108357|
Well just to stoke the fire a little. We never heard why Matt had a sudden unplanned trip to New York. Could he have been meeting with someone important? I have no clue but have wishful thinking. LOL
Just to add, I see three reasons a company should want to invest in CBAI.
1) Profit - Drives all companies and it's clear there are profits to be made in private banking
2) Seat at the Table - A Director or two added to our Board to help take the company in the direction they prefer
3) Growth - With a major company buying preferred shares they could expedite growth much more rapbidly while protecting there investment
I can't help but think the more good things that keep happening related to private storing, a major pharma or insurance company will want to buy into a private banking company. The two largest players today in the US are CBR and Viacord, both of which are privately held today so unless they want to sell they are not options. Cryo Cell is next and then Cord Blood America. And we actually have a larger storage facility than Cryo Cell. Any day it could happen without warning. In the meantime, each quarter our financials are improving.
All have a great weekend.
Looks like today might be short covering day so the MM's will take it down to scare some into selling. Not me.
Mr Long. Is there anything you can share with this Board on what is happening with the Medicare change and CBAI?
Morning Mr Long and all. In fact the patent ended March 31, 2010. CBAI has been accruing the royalty for there Cord Partner related revenue but have not paid it as they don't feel they have too due to the other court finding related to Corcell. Once that is settled, I think there is around $400K that could be reversed which would all fall to the bottom line profit number. Maybe they reverse it in 4Q this year to help make them profitable for the first time ever?
Really the only impact the current share price has on CBAI is if they sell some shares to cover any cash flow requirements. The cheaper they have to sell them the more they will have to sell to raise the same amount of funds. Nobody including the CEO truly totally understands why the current decreased share value. It's clear for now the MM's are shorting but they can't be making much money doing it at these low volumes. At some point you would think the MM's will get bored with this and move on. Could happen any day and when it does we'll have a very nice run. In the meantime, Matt is doing the right thing and that is implementing his strategy to improve the financials and that is happening in spite of the share price issue. Eventually that will bring more eyes to this stock and the share price will show a more fair value. As I asked earlier, what would a fair share price be if we make a small profit? That could happen in 4Q10 or more likely 1Q11 IMO.
Very low short volume yesterday at 9%. But 52% today. Hmmm.
20100601|CBAI|1244000|13826563
20100602|CBAI|9762359|18747132
For fun what do people think this PPS will be the first time CBAI actually returns a profit? Any profit. Then, when do you think that might happen? Ignore the pps today and just focus on that because it's not going to be that far in the future the way things are going.
Can't argue with any of that. Few probably understand that CBAI wrote off the entire cost of acquiring a 51% interest in Stellacure in the 1st quarter ($820K). So no longterm write off coming for that. I would assume if they acquire Biocells they will do the same thing. That's good for us investors because expectations are low right now for the financials and those kinds of actions will set us up to be profitable sooner. And also as I posted earlier, few probably have read the China deal which lays out minimum revenue (royalties) payments as part of the deal. So even if Newco (new AXMP sub), which has yet to be announced, fails to make there targets they have to cut us a predetermined check and the amount goes up each quarter. Plus, it's clear there is room to expand in China with this deal which could be huge for this company. All profit. Matt's job is not to manage the share price but to implement his business plan and strategy and that is what he is doing. This company could be a goldmine and I feel few here have that understanding/vision.
Yes. All of a sudden this morning it stopped appearing. Don't know if it's permanent or temporary but it was a good source of info.
There is no reverse spilt on the horizon. Regardless of some peoples opinion. Patience all. This is a great long-term investment IMO. Period. And this short attack is meant to pry cheap shares from concerned investors but is temporary for sure.
The simple answer to your question is CBAI is working thru all this with Mr Long's help, and when ready we will hear something from CBAI. In order to obtain maximum benefit from these changes some things have to be clarified.
And when I say I'm Long, that also means I have patience. I expect to see 50% revenue growth in 2Q, 100% revenue growth in 3Q, and 200% revenue growth in 4Q assuming we close the Biocells deal. I consider that progress for sure. And next year the China deal starts paying off. Did you know we have minimum revenue payments guaranteed in the contract with AXMP? It's in the annual 10K that came out recently. You might want to read it.
Is anyone else signed up for CBAI news on the CBAI website? I got this tonight. Nice.
Cord Blood America News
--------------------------------------------------------------------------------
Cord Blood America (OTC BB: CBAI): In The News
Posted: 01 Jun 2010 03:35 PM PDT
Cord Blood America (OTC BB: CBAI) is the stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally. This clipping service will keep you up-to-date on accomplishments in this important health arena.
Cord Blood Stem Cells - A Global Market Overview
Global cord blood stem cells market for 2010 is estimated at about US$4.5 billion. The market is further projected to register a robust CAGR of 27.3% during the period 2006-2015 to reach US$15 billion by 2015.
Umbilical cord and placenta, once considered medical waste are emerged to be a valuable source of stem cells. The cord blood stem cells show the potential to treat the fatal diseases such as leukemia, cardiac attacks and debilitating diseases including Alzheimer's and Parkinson's. Cord blood stem cells are also widely used in therapies such as blood disorders, bone and tissue engineering, dermatology and diabetes.
A new study "Cord Blood Stem Cells - A Global Market Overview" reviews, analyzes and projects the global market for Cord Blood Stem Cells for the period 2006-2015.
Key Trends
Stem cells from umbilical cord blood may be used to build new heart valves to be implanted in children with congenital heart problems. So far in infants with faulty heart which cannot be surgically treated the options were to use donated human organs, artificial materials, or replacement from animal tissue.
"Family Cord Blood Banking Act" changes the hitherto followed IRS code and provides tax incentives and allow payment for umbilical cord blood banking through Medical expenses tax deduction, Health Savings Account (HSA), Flexible Spending Accounts (FSA), Health Reimbursement Arrangements (HRS) and Medical savings Account.
Statistics on umbilical cord transplant reveals an upward trend and this is due to the success of research in cord blood, tests and transplant procedures. This reiterates the fact that umbilical cord transplant has been useful in providing treatments to many diseases and many people are opting for this treatment.
The cord blood stem cells are capable of migrating to the injured cardiac tissue; improve blood flow, vascular function and the overall heart function. Nutrients and oxygen are brought to the part of the damaged heart via the blood to help in recovery. The volume of blood should be high which is where the cord blood stem cells come to the rescue as these cells are capable of giving rise to vascular endothelial like cells.
Leukemia Patient at 4
By CBS News Medical Correspondent Dr. Jon LaPook and CBS News Producer Phil Hirschkorn
When 20-month-year-old Devan Tatlow was diagnosed with a rare form of leukemia in 2007, his parents were devastated but determined that their only child could beat the disease.
"It was a complete nightmare" his mother, Indira Lakshmanan, tells CBS News. "We were shocked."
The family, which had just arrived in China for a job change, abruptly returned to the United States. Devan spent four months in Boston Children's Hospital, undergoing chemotherapy, then losing his hair and eyelashes.
"What they certainly didn't take from him was his spirit," his father, Dermot, told CBS News. "He's a brave kid."
Devan's cancer went into remission. He turned four last November. The family moved to Washington, D.C. Life seemed to move on.
"We really thought we dodged that, we were done, he was cured. And we found out we were wrong," Indira says.
Wrong because last month routine testing showed the leukemia was back.
Devan's doctors, led by pediatric oncologist Dr. Aziza Shad at Georgetown University Hospital, believe Devan's best hope for survival is a bone marrow transplant, which are sought by nearly 15,000 Americans with diseases such as leukemia and lymphoma every year.
But finding a genetic match for such a transplant isn't that easy when the patient is mixed race or a racial minority. No match has been found for Devan, whose mother is half Indian and whose father is Irish.
"It's the children who come from ethnic minorities, the children who come from multiracial backgrounds - that's where we have a problem," Dr. Shad told CBS News.
Ultimately, about two-thirds of whites are able to find and receive a bone marrow transplant, according to the National Marrow Donor Program. But the odds are only 50-50 for those of mixed race, according to Dr. Willis Navarro, NMDP Medical Director for Transplant Services.
For Hispanics and Asians, only four of every ten seeking a bone marrow transplant succeed in getting one, while only one-third of African-Americans do, Navarro said.
"We had a beautiful 19-year-old African-American woman, who desperately needed to go to transplant, because of her disease. In spite of looking for months for a good donor for her, we were unsuccessful, and we lost her last month," Dr. Shad said.
With no bone marrow match in hand, Devan's doctors have pinned their hopes on cord blood, which is collected at the time of birth from umbilical cords and placentas that would otherwise be discarded. Cord blood has stem cells that can replace diseased bone marrow.
Indira says, "Devan is an only child. He's everything. He's our life."
Father continues mission after daughter's death.
Tami S. Zimmerman
CNYLink
5/28/10
Warm. Compassionate. Brilliant. Gorgeous.
Words family and friends use to describe Natasha Collins, a longtime Manlius, New York, resident who last year lost her battle to leukemia.
"[Natasha] was as close to perfect as someone can be," said her high school friend Genevieve Pandori. "She had such a great attitude and was always upbeat and positive. Natasha was truly someone who was beautiful on the inside and out."
Collins was 25 years old when she was first diagnosed. Her chance for a cure, however, was dramatically lessened because she was of mixed heritage; her father an African-American, her mother an Irish American. The relation to a cure is almost always a direct result of being able to locate a perfectly or partially matched bone marrow donor.
It is impossible for people of mixed heritage to find a perfectly matched bone marrow donor due to their genetic diversity. Those people of mixed heritage that are fortunate enough to find a partially matched donor frequently suffer or die from graft versus host related diseases.
Collins died from complications involving a partially matched bone marrow transplant to treat her leukemia. But there was an alternative. Had she been able to receive a cord blood transplant she would likely still be alive today. Yale-New Haven Hospital, where Collins was attending medical school and also received her transplant, however, only performs bone marrow transplants for adults.
Cord blood is obtained from the umbilical cord that links a mother and child. The blood present in the umbilical cord is a rich source of the same stem cells found in bone marrow.
"Partially matched cord blood stem cells from an unrelated donor, however, offer the advantage of never causing the life-threatening responses that frequently occur when partially matched, unrelated bone marrow stem cells are used for a transplant," said Dr. Tedd Collins, a clinical immunologist and Natasha's father. "That means your chance of surviving a transplant and, therefore, your disease, is much, much greater."
After his daughter's death, Dr. Collins refocused two organizations that Natasha helped to create before she died to help save the lives of others trapped in the same situation.
"Natasha's Place and Become My Hero honor her struggle," Dr. Collins said. "Our combined mission is very simple. We are here to insure that all individuals receive equal access to the life saving potential of effectively safe stem cell transplants, not because it's good business but because it's our moral imperative."
Transplant physicians have been performing cord blood transplants for a quarter of a century, and although they are not as established as bone marrow transplants, they are on the rise, and according to Dr. Collins, will likely be the transplant of choice in the near future.
"Several transplant centers, including the University of Minnesota, only do cord blood transplants because they are much safer and provide the same effective benefit to patients," he said.
Today, Become My Hero is working with 10 people who either don't have or can't find a bone marrow donor. Once it's determined who will be their best cord blood matches, Dr. Collins said they would search the globe to find their donors.
"We are currently trying to save the life of a young, Canadian hockey star, said Dr. Collins, who has been recently featured in many articles and news interviews, including CBC Canada. "We will be doing cord blood collection in North America and Germany in hopes of finding her a donor. These are the kind of things that were spurred on by my daughter's death."
Most people typically find out about Become My Hero through word of mouth, bone marrow recruitment organizations and other cancer victims. To learn more about Become My hero, visit BecomeMyHero.org.Additionally, if you do not need a stem cell donor but are pregnant and interested in learning more about privately banking or donating your cord blood visit NatashasPlace.org
"We will miss [Natasha] always and the world would definitely be a better world with her in it," Dr. Collins said. "But hopefully, a little piece of her will continue to help others live the life she didn't."
I was hoping CBAI was going to be todays pick on Stockhideout but it's not us. Damn.
Hope I'm right. Thought you would like that.
The only thing that will pull us out of this is volume. And we might?????? get that today???? I'll answer your question after the market opens.